FutureChem Co.,Ltd (KOSDAQ:220100)

Market Cap	551.32B
Revenue (ttm)	15.73B
Net Income (ttm)	-10.57B
Shares Out	22.10M
EPS (ttm)	-478.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	279,877
Average Volume	508,180
Open	24,300
Previous Close	24,300
Day's Range	24,300 - 25,100
52-Week Range	8,610 - 31,250
Beta	1.47
RSI	70.83
Earnings Date	Mar 17, 2025

About FutureChem Co.,Ltd

FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of athe...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1999
• Employees: 66
• Stock Exchange: KOSDAQ
• Ticker Symbol: 220100

Financial Performance

In 2023, FutureChem Co.,Ltd's revenue was 13.97 billion, an increase of 11.09% compared to the previous year's 12.57 billion. Losses were -6.71 billion, -51.94% less than in 2022.